GNS
Desconocido
MEUSIX: Clinical trial of gene therapy for MPS VI a severe lysosomal storage disorder
GENOSAFE SAS
participó en un
FP7:
"Mucopolysaccharidosis VI (MPS VI, or Maroteaux-Lamy syndrome; OMIM #253200) is a rare lysosomal storage disease caused by deficient activit...
Financiado
Financiado
TARGETAMD: Transposon based targeted ex vivo gene therapy to treat age related macular degeneration AMD
GENOSAFE SAS
participó en un
FP7:
Age-related Macular Degeneration (AMD), a neurodegenerative disease of the retina, is a major cause of blindness in elderly people. Due to t...
Financiado
Financiado
* No se disponen de datos de la empresa actual.